

# Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

10/11/2023

SAN DIEGO--(BUSINESS WIRE)-- **Primmune Therapeutics**, a biotech company harnessing the power of the innate immune system, today announced the upcoming presentation of new clinical data from its Phase 1 study of PRTX007, an orally administered prodrug of a novel, small molecule toll-like receptor 7 (TLR7)-specific agonist, at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting). The poster presentation will highlight the suitability of PRTX007 for investigation in combination therapy for curative treatment of chronic hepatitis B virus (HBV) infection.

The Liver Meeting will be held in Boston from November 10-14. An e-poster will be made available in the online meeting portal during the event.

## Presentation details:

**Title:** Clinical validation of an orally-delivered, systemically activated TLR7 agonist to boost host immune response to chronic viral diseases, including hepatitis B virus

**Presenting Author:** Curtis L. Scribner, M.D.

**Poster ID:** 1463-C

**Presentation Date and Time:** Friday, November 10 - 12:00 PM – 1:00 PM ET

**Location:** Hynes Convention Center, Hall C (second floor)

## About PRTX007

PRTX007, Primmune's lead clinical development candidate, is designed to provide well-tolerated, controlled, long-term stimulation of the innate immune response while also potentiating long-term effective innate and adaptive immune responses. PRTX007 administration uniquely activates plasmacytoid dendritic cells (pDCs), leading to a systemic immune poly-IFN response without stimulating production of NF-κB-driven proinflammatory factors like IL-6, TNFα or IL-1β. Activated pDCs directly deliver interferons to target cells by paracrine transfer. Conceptually, this is equivalent to administering a therapeutically effective cocktail of all Type I/III IFNs while avoiding the associated side effects and adverse events. Furthermore, PRTX007 administration leads to systemic activation of anti-tumor effector CD8+ T cells and NK cells.

## About Primmune Therapeutics

Primmune Therapeutics is a clinical-stage biotech harnessing the power of the innate immune system by developing small molecule, orally administered toll-like receptor 7 (TLR7) agonists. For more information, please visit <https://www.primmunerx.com/>.

### Media:

#### MacDougall Advisors

Karen Sharma

[ksharma@macdougall.bio](mailto:ksharma@macdougall.bio)

781-235-3060

Source: Primmune Therapeutics